Moderna's Ebola Vaccine Candidate Selected for WHO-Recommended Phase 2/3 Trial
Moderna (MRNA) has received a recommendation from a World Health Organization expert panel to proceed with a Phase 2/3 clinical study for its mRNA-based Ebola vaccine, mRNA-1469. The clinical trial, titled 'Tumaini,' is being conducted in the Democratic Republic of the Congo. The development marks a significant step in applying mRNA technology to infectious disease prevention outside of COVID-19 applications. By moving into late-stage testing in an endemic region, Moderna aims to validate the efficacy and safety of its candidate against the Ebola virus.
Tickers: $MRNA
Topics: clinical trials Ebola vaccine mRNA technology WHO recommendation
Read the full article at Seeking Alpha
Part of the story Moderna says Ebola vaccine picked for Phase 2/3 trial in Africa (2 articles)